What is the appropriate antiplatelet therapy for a patient with end-stage renal disease (ESRD) and coronary vascular disease, without atrial fibrillation?

Antiplatelet Therapy for ESRD Patients with Coronary Disease (Without Atrial Fibrillation)

Primary Recommendation

For patients with ESRD and coronary vascular disease without atrial fibrillation, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is recommended for 12 months following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), followed by single antiplatelet therapy (SAPT) indefinitely. 1

---

Initial Management Following ACS or PCI

Acute Phase (First 12 Months)

Aspirin:

• Loading dose: 150-300 mg orally (or 75-250 mg IV) 1
• Maintenance dose: 75-100 mg daily long-term 1

P2Y12 Inhibitor Selection:

• Prasugrel is preferred for patients proceeding to PCI (60 mg loading dose, then 10 mg daily; reduce to 5 mg daily if age ≥75 years or weight <60 kg) 1
• Ticagrelor is an alternative (180 mg loading dose, then 90 mg twice daily) regardless of invasive or conservative strategy 1
• Clopidogrel (300-600 mg loading dose, then 75 mg daily) should only be used when prasugrel or ticagrelor are unavailable, not tolerated, or contraindicated 1

---

Critical Considerations for ESRD Patients

Bleeding Risk Assessment

ESRD patients have substantially elevated bleeding risk that must be balanced against thrombotic risk 1:

• Renal failure requiring dialysis or eGFR <15 mL/min/1.73 m² is explicitly defined as an increased risk of major bleeding 1
• This population was specifically identified as having contraindications to extended DAPT beyond 12 months in the 2020 ESC guidelines 1

High Bleeding Risk (HBR) Modifications

For ESRD patients classified as high bleeding risk (HBR):

• Consider shortening DAPT duration to 3-6 months after ACS, then transition to SAPT 1
• After 6 months post-ACS (or 3 months post-stable disease PCI), continue with aspirin 75-100 mg daily alone as SAPT 1
• Clopidogrel 75 mg daily may be used as the sole antiplatelet agent if aspirin is not tolerated 1

---

Long-Term Management (Beyond 12 Months)

Standard Approach

Single antiplatelet therapy (SAPT) with aspirin 75-100 mg daily is recommended after completing 12 months of DAPT 1:

• This applies to patients with stable coronary disease or those >12 months post-ACS/PCI 1
• Antiplatelet therapy beyond 12 months with DAPT is NOT recommended in stable patients due to lack of efficacy and increased major bleeding risk 1

Extended DAPT Considerations

Extended DAPT (>12 months) may be considered only if:

• Patient has high ischemic risk (prior MI, complex lesions, extensive atherosclerotic disease) 1
• Patient has low bleeding risk (which explicitly excludes ESRD patients with eGFR <15 mL/min or dialysis-dependent) 1
• Given ESRD patients are inherently high bleeding risk, extended DAPT is generally contraindicated 1

---

Special Populations Within ESRD

Patients with Moderate CKD (Stage 3, CrCl 30-59 mL/min)

• Standard DAPT duration and agent selection apply 1
• Monitor renal function every 3-6 months as declining function may necessitate strategy adjustment 1

Patients on Hemodialysis or CrCl <15 mL/min

• Minimize DAPT duration to reduce bleeding complications 1
• Transition to SAPT as soon as clinically appropriate (6 months post-ACS minimum) 1
• Avoid concomitant anticoagulation unless absolutely necessary (e.g., mechanical valve, high-risk AF) 1

---

Critical Pitfalls to Avoid

Do NOT Use Anticoagulation Without AF

Oral anticoagulation is NOT indicated for coronary disease alone in patients without atrial fibrillation 1:

• The question specifically excludes AF, so warfarin or DOACs should not be prescribed for coronary disease management 1
• Combining anticoagulation with antiplatelet therapy dramatically increases bleeding risk, particularly in ESRD 1

Avoid Underdosing or Overdosing P2Y12 Inhibitors

• Do not reduce prasugrel or ticagrelor doses based solely on renal function unless specific criteria are met (age ≥75 years or weight <60 kg for prasugrel) 1
• Clopidogrel requires no dose adjustment for renal impairment 1

Monitor for Drug Interactions

• Avoid proton pump inhibitors (PPIs) with clopidogrel when possible, as they reduce clopidogrel efficacy 1
• PPIs do not significantly interact with prasugrel or ticagrelor 1

---

Practical Algorithm Summary

For ESRD patients with coronary disease and NO atrial fibrillation:

1. Acute phase (0-12 months post-ACS/PCI):

   • Aspirin 75-100 mg daily + Prasugrel 10 mg daily (or 5 mg if age ≥75 or weight <60 kg) 1
   • Alternative: Aspirin + Ticagrelor 90 mg twice daily 1

2. High bleeding risk modification (ESRD with dialysis or eGFR <15):

   • Consider shortening DAPT to 6 months post-ACS 1

3. Chronic phase (>12 months):

   • Aspirin 75-100 mg daily alone (SAPT) 1
   • Do NOT continue DAPT beyond 12 months in ESRD patients 1

4. Monitoring:

   • Reassess bleeding and ischemic risk at each visit 1
   • Monitor renal function every 3-6 months 1
   • Evaluate for signs of bleeding (GI symptoms, anemia, bruising) 1